Abstract: It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.

Abstract: It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.

Abstract: The present invention provides an apparatus including: a container that receives urine; and a urine amount measuring device that measures the weight of the urine received by the container; wherein the urine amount measuring device has: a mounting plate, which is a plate on which the container is mounted; a measuring portion that measures the weight of the container mounted on the mounting plate multiple times at given time intervals; and an output portion that outputs a result of the measurement performed by the measuring portion, and the apparatus has a fixing structure that is situated in at least a bottom portion of the container and a mounting face of the mounting plate and that detachably fixes the container on the mounting plate.

Abstract: The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.

Abstract: The present invention provides an apparatus including: a container that receives urine; and a urine amount measuring device that measures the weight of the urine received by the container; wherein the urine amount measuring device has: a mounting plate, which is a plate on which the container is mounted; a measuring portion that measures the weight of the container mounted on the mounting plate multiple times at given time intervals; and an output portion that outputs a result of the measurement performed by the measuring portion, and the apparatus has a fixing structure that is situated in at least a bottom portion of the container and a mounting face of the mounting plate and that detachably fixes the container on the mounting plate.

Abstract: Conventional measuring apparatuses and the like have the problem of not being able to accurately measure information inside the living body. The present invention provides a measuring apparatus disposed inside the living body, comprising: a sensor portion 101 that has an accepting unit 1011 accepting a physical quantity that is to be measured and a signal acquiring unit 1012 acquiring a detection signal, which is a signal corresponding to a result of the acceptance of the accepting unit 1011; a signal output portion 102 that wirelessly outputs the detection signal to the exterior; and a vessel 106 in which at least the signal acquiring unit 1012 of the sensor portion 101 and the signal output portion 102 are sealed.

Abstract: The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.